Pre-Open 01/10: (SRNE) (SNX) (DERM) Higher (PTLA) (SIX) (SPWH) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Ultragenyx Pharma (RARE), Kyowa Kirin Report Submission of Supplemental Biologics License Application to FDA for Crysvita (burosumab)
January 13, 2020 8:18 AM ESTUltragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd., (TYO: 4151) today announced that they submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) on December 18, 2019, for Crysvita® (burosumab) for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors (tumor-induced osteomalacia; TIO) that cannot be curatively resected or localized. The companies expect to hear back from FDA on submission acceptance and review designation in February... More
Needham & Company Upgrades NVIDIA (NVDA) to Hold
January 13, 2020 7:25 AM ESTNeedham & Company analyst Rajvindra Gill upgraded NVIDIA (NASDAQ: NVDA) from Underperform to Hold.
The analyst comments "We are upgrading NVIDIA to Hold from Underperform following our positive meeting at CES. When we downgraded the shares to an Underperform in Jan. '19, we were... More
NVIDIA (NVDA) PT Raised to $300 at Evercore ISI
January 13, 2020 7:22 AM ESTEvercore ISI analyst C.J. Muse raised the price target on NVIDIA (NASDAQ: NVDA) to $300.00 (from $225.00) while maintaining a Outperform rating.
... More